Literature DB >> 24566708

Donor-derived CD4(+)/CCR7(+) T-cell partial selective depletion does not alter acquired anti-infective immunity.

B Choufi1, J Trauet2, S Thiant2, M Labalette2, I Yakoub-Agha3.   

Abstract

In previous studies, we observed that a high proportion of donor-derived CD4(+) T cells expressing the chemokine receptor 7 (CCR7) was a major determinant of acute GVHD, without interfering with the incidence of other post-transplant outcomes, especially relapse and nonrelapse mortality rates. Here, we investigated in vitro the impact of partially selective CD4(+)/CCR7(+) T lymphocytes on acquired anti-infective immune response in 10 donors who underwent G-CSF-primed PBSC collection. Similar quantitative and functional proliferative reactions were observed in lymphocyte cultures in the presence of adenovirus and pp65 Ags with unmanipulated and partially depleted donor samples. No responses were observed in the presence of human T-cell lymphotropic virus type 1 used as a negative control. These results complete the proof of concept needed to build a clinical trial investigating partially selective CD4(+)/CCR7(+) T cell-depleted allo-SCT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24566708     DOI: 10.1038/bmt.2014.6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  41 in total

1.  Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus-infected endothelial cells: role of MHC class I antigens.

Authors:  A Weinberg; L Zhang; A R Hayward
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

2.  Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells.

Authors:  M Ahmadzadeh; S F Hussain; D L Farber
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

Review 3.  Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL).

Authors:  F R Appelbaum
Journal:  Leukemia       Date:  1997-05       Impact factor: 11.528

4.  Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.

Authors:  Pedro Romero; Alfred Zippelius; Isabel Kurth; Mikaël J Pittet; Cédric Touvrey; Emanuela M Iancu; Patricia Corthesy; Estelle Devevre; Daniel E Speiser; Nathalie Rufer
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

5.  Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.

Authors:  James M Coghill; Michael J Carlson; Angela Panoskaltsis-Mortari; Michelle L West; Joseph E Burgents; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

6.  L-selectin (CD62L) blockade does not impair peritoneal neutrophil emigration or subcutaneous host defense to bacteria in rabbits.

Authors:  S R Sharar; N N Chapman; L C Flaherty; J M Harlan; T F Tedder; R K Winn
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

7.  Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.

Authors:  Alexandre Harari; G Paolo Rizzardi; Kim Ellefsen; Donatella Ciuffreda; Patrick Champagne; Pierre-Alexandre Bart; Daniel Kaufmann; Amalio Telenti; Roland Sahli; Giuseppe Tambussi; Laurent Kaiser; Adriano Lazzarin; Luc Perrin; Giuseppe Pantaleo
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.

Authors:  Hartmut Bertz; Alexandros Spyridonidis; Ralph Wäsch; Carsten Grüllich; Mathias Egger; Jürgen Finke
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-01       Impact factor: 5.742

9.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

10.  Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.

Authors:  Elisabeth Amyes; Chris Hatton; Damien Montamat-Sicotte; Nancy Gudgeon; Alan B Rickinson; Andrew J McMichael; Margaret F C Callan
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.